The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 6, 2011, Pages 353-365

  Donath, F ^a   Braeter, M ^b   Feustel, C ^b  

^a SocraTec R and D GmbH   (Germany)

^b APOGEPHA Arzneimittel GmbH   (Germany)

Author keywords

Cardiac repolarization; Drug safety; Propiverine; QTc prolongation; Torsades de pointes

Indexed keywords

PLACEBO; POTASSIUM; PROPIVERINE;

ADULT; AGED; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ECG ABNORMALITY; EXERCISE TEST; FEMALE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; T WAVE; XEROSTOMIA;

ADULT; AGED; BENZILATES; CHOLINERGIC ANTAGONISTS; CORONARY DISEASE; CROSS-OVER STUDIES; CYCLIC N-OXIDES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; POTASSIUM;

EID: 79959393394     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201443     Document Type: Article

References (48)

1. Carlsson L. Drug-induced torsade de pointes: the perspectives of industry. Eur Heart J. 2001; 3: K114-K120.
2. CPMP. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products (CPMP/986/96). 17 Dec 1997.
3. Health Canada. Assessment of the QT prolongation potential of non-antiarrhythmic drugs. 15 Mar 2001.
4. CHMP. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (CHMP/ICH/2/04, ICH-topic E14). Nov 2005.
5. Madersbacher H, Mürtz G. Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol. 2001; 19: 324-335. (Pubitemid 33777078)
6. Connolly MJ, Astridge PS, White EG, Morley CA, Cowan JC. Torsades de pointes ventricular tachycardia and terodiline. Lancet. 1991; 338: 344-345.
7. Stewart DA, Taylor J, Ghosh S, Macphee GJ, Abdullah I, McLenachan JM, Stott DJ. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol. 1992; 42: 577-580.
8. Christ T, Wettwer E, Wuest M, Braeter M, Donath F, Champeroux P, Richard S, Ravens U. Electrophysiological profile of propiverine-relationship to cardiac risk. Naunyn Schmiedebergs Arch Pharmacol. 2008; 376: 431-440.
9. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart. 1920; 7: 353-370.
10. Hreiche R, Morissette P, Zakrzewski-Jakubiak H, Turgeon J. Gender-related differences in drug-induced prolongation of cardiac repolarization in prepubertal guinea pigs. J Cardiovasc Pharmacol Ther. 2009; 14: 28-37.
11. Haverkamp W, Mönnig G, Kirchhof P, Eckardt L, Borggrefe M, Breithardt G. Torsade de pointes induced by ajmaline. Z Kardiol. 2001; 90: 586-590.
12. Laaho M, Aberg A, Savola J, Pentikäinen PJ, Pyörälä K. Diseases and drugs causing prolongation of the QT interval. Am J Cardiol. 1987; 59: 862-865.
13. Krikler DM, Curry PV. Torsade De Pointes, an atypical ventricular tachycardia. Br Heart J. 1976; 38: 117-120.
14. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med. 2004; 164: 943-948. (Pubitemid 38581512)
15. Furukawa T, Kurokawa J. Regulation of cardiac ion channels via non-genomic action of sex steroid hormones: implication for the gender difference in cardiac arrhythmias. Pharmacol Ther. 2007; 115: 106-115. (Pubitemid 46990555)
16. APOGEPHA. Mictonorm® 15 mg Coated Tablets (Summary of Product Characteristics). 27 Oct 2005.
17. MHRA. Public Assessment Report: Mictonorm XL 30 mg Modified Release Capsules, Propinorm XL 30 mg Modified Release Capsules (PL 15072/0006, PL 15072/0007). 13 Feb 2008.
18. Gertsch M. Das EKG. Berlin-Heidelberg: Springer; 2009. p. 569-588.
19. Richter K, Scheithauer S, Thümmler D. High-performance liquid chromatographic determination of propiverine and its N-oxide in human serum. J Chromatogr B Biomed Sci Appl. 1998; 708: 325-329.
20. May K, Westphal K, Giessmann T, Wegner D, Adam U, Lerch MM, Oertel R, Warzok RW, Weitschies W, Braeter M, Siegmund W. Disposition and antimuscarinic effects of the urinary bladder spasmolytics propiverine: influence of dosage forms and circadian-time rhythms. J Clin Pharmacol. 2008; 48: 570-579. (Pubitemid 351503515)
21. May K, Giessmann T, Wegner D, Oertel R, Modess C, Oswald S, Braeter M, Siegmund W. Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination. Eur J Clin Pharmacol. 2008; 64: 1085-1092.
22. Health Canada. Release of final Health Canada document: Health Canada Question and Answer Document Regarding the ICH S7B and E14 Guidances. 30 Nov 2006.
23. Michel MC, Hegde SS. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol. 2006; 374: 79-85.
24. Wuest M, Hecht J, Christ T, Braeter M, Schoeberl C, Hakenberg OW, Wirth MP, Ravens U. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Br J Pharmacol. 2005; 145: 608-619. (Pubitemid 41032633)
25. Wuest M, Weiss A, Waelbroeck M, Braeter M, Kelly LU, Hakenberg OW, Ravens U. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Naunyn Schmiedebergs Arch Pharmacol. 2006; 374: 87-97. (Pubitemid 44657615)
26. 2+ transients in murine urinary bladder myocytes. J Pharmacol Exp Ther. 2008; 324: 118-127. (Pubitemid 350294167)
27. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res. 2003; 58: 32-45. (Pubitemid 36351620)
28. Dorschner W, Stolzenburg JU, Griebenow R, Halaska M, Schubert G, Mürtz G, Frank M, Wieners F. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur Urol. 2000; 37: 702-708.
29. Jünemann KP, Hessdörfer E, Unamba-Oparah I, Berse M, Brünjes R, Madersbacher H, Gramatté T. Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder. Urol Int. 2006; 77: 334-339. (Pubitemid 44837003)
30. Habib G. Reappraisal of the importance of heart rate as a risk factor for cardiovascular morbidity and mortality. Clin Ther. 1997; 19 (Suppl A): 39-52.
31. Lanza GA, Fox K, Crea F. Heart rate: a risk factor for cardiac diseases and outcomes? Pathophysiology of cardiac diseases and the potential role of heart rate slowing. Adv Cardiol. 2006; 43: 1-16. (Pubitemid 44290159)
32. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007; 100: 987-1006. (Pubitemid 47537675)
33. Andersson KE, Olshansky B. Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. BJU Int. 2007; 100: 1007-1014. (Pubitemid 47537647)
34. +) currents and action potentials. Br J Pharmacol. 2000; 131: 245-254.
35. Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007; 81: 377-385. (Pubitemid 46364489)
36. Homma Y, Yamaguchi O; Imidafenacin Study Group. A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. Int J Urol. 2009; 16: 499-506.
37. Blume H, Schug B, Wonnemann M, Donath F. Safety and tolerability of propiverine hydrochloride (Mictonorm®) in patients with severe renal impairment (SRI). 8/31/05, 9/2/05 ICS 2005.
38. Siepmann M, Nokhodian A, Thümmler D, Kirch W. Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Eur J Clin Pharmacol. 1998; 54: 767-771. (Pubitemid 29024212)
39. CHMP. The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (CHMP/ICH/423/02 S7B). 25 May 2005.
40. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf. 2001; 24: 323-351. (Pubitemid 32417533)
41. Sarapa N, Morganroth J, Couderc JP, Francom SF, Darpo B, Fleishaker JC, McEnroe JD, Chen WT, Zareba W, Moss AJ. Electrocardiographic identification of drug-induced QT prolongation: assessment by different recording and measurement methods. Ann Noninvasive Electrocardiol. 2004; 9: 48-57. (Pubitemid 38230430)
42. Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK. Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol. 2006; 46: 598-612.
43. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol. 2001; 12: 411-420. (Pubitemid 32324653)
44. Malik M, Färbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002; 87: 220-228. (Pubitemid 34177674)
45. Milic M, Bao X, Rizos D, Liu F, Ziegler MG. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist- induced QTc prolongation. Clin Ther. 2006; 28: 582-590. (Pubitemid 43783443)
46. Piotrovsky V. Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J. 2005; 7: E609-E624.
47. Démolis JL, Vacheron F, Cardus S, Funck-Brentano C. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther. 2003; 73: 242-252.
48. Nagy D, DeMeersman R, Gallagher D, Pietrobelli A, Zion AS, Daly D, Heymsfield SB. QTc interval (cardiac repolarization): lengthening after meals. Obes Res. 1997; 5: 531-537.